Results 111 to 120 of about 2,201,777 (199)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

, 2019
Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung ...
Roberta Minari, Giovannetti E., Marcello Tiseo, Perego, Paola, Tiseo M., Tiseo, Marcello, Leonetti, Alessandro, Minari R., Sharma, Sugandhi, Sugandhi Sharma, Elisa Giovannetti, Minari, Roberta, Leonetti A., Perego P., Paola Perego, Sharma S., Alessandro Leonetti, Giovannetti, Elisa   +17 more
core   +1 more source

Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer

Frontiers in Oncology
Osimertinib, a third-generation inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, exhibits remarkable efficacy in prolonging the survival of patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations, surpassing the ...
Beilei Zeng, Beilei Zeng, Kelun Gan, Yuanhang Yu, Jianping Hu, Jianping Hu, Qiao Deng, Qiao Deng, Chong Yin, Chong Yin, Xi Gao, Xi Gao   +11 more
doaj   +1 more source

INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

: MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibitor,
Raskin, Jo, Morise, Masahire, Wu, Yi-Long, Dooms, Christophe, Tan, Daniel, Nadal, Ernest, Smit, Egbert F., Hin, How S., Zhu, Viola W., Karachaliou, Niki, Ellers-Lenz, Barbara, Holmberg, Kristina H., Schumacher, Karl M., Adrian, Svenja, Brutlach, Sabine, Tho, Lye M., Le, Xiuning, Mazieres, Julien   +17 more
core  

Hypoxia-inducible APCDD1L-AS1 promotes osimertinib resistance by stabilising DLST to drive tricarboxylic acid cycle in lung adenocarcinoma

Journal of Experimental & Clinical Cancer Research
Acquired resistance is unavoidable in lung adenocarcinoma (LUAD) treated with osimertinib, however, the underlying mechanisms remain largely unknown.
Quanli Zhang, Ye Shen, Yuru Che, Lili Jia, Xiang Xiao, Hao Xu, Chi Su, Kemin Sun, Limin Zheng, Jiawen Xu, Jingwen Hu, Chaofeng Zhang, Dihan Zhu, Ming Li   +13 more
doaj   +1 more source

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report

HER2 mutations have been identified as potential mechanisms of resistance to EGFR-directed therapies in patients with advanced or metastatic NSCLC. Here, we report the case of a 65-year-old female with metastatic, EGFR exon 19–mutant NSCLC initially ...
Hailey M. Hirata, PharmD, Kevin Y. Chen, PharmD, MS, Carrie B. Lee, MD, MPH   +2 more
core   +1 more source

circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)

Molecular Cancer
Background Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are involved in the occurrence and development of a variety of tumors. The aim of this study was to investigate the effects of circ_PPAPDC1A in
Yi-fang Tang, Zheng-hua Liu, Lei-yi Zhang, Sheng-hao Shi, Shun Xu, Jin-An Ma, Chun-Hong Hu, Fang-wen Zou   +7 more
doaj   +1 more source

Dihydroartemisinin Mitigates Osimertinib Resistance in Lung Adenocarcinoma through Modulation of the EMT Transcription Factor Slug

Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is associated with a complex array of resistance pathways. Epithelial-mesenchymal transition (EMT) represents a mechanism contributing to resistance development in epidermal ...
He, Gangfeng, Li, Yankang, Wang, Junjie
core   +1 more source

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

, 2018
Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs. Acquired EGFR C797S mutation has
Yi Xiang, Xiaoling Tong, Yang W. Shao, Tao Jiang, Hua Bao, Zhe Yang, Caicun Zhou, Qiuxiang Ou, Xiaonan Wang, Yunpeng Liu, Yan Wang, Nong Yang, Xue Wu   +12 more
core   +1 more source

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Experimental and Molecular Medicine
Osimertinib, a selective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), effectively targets the EGFR T790M mutant in non-small cell lung cancer (NSCLC).
Wonyoung Park, Shibo Wei, Chu-Long Xie, Jung Ho Han, Bo-Sung Kim, Bosung Kim, Jung-Sook Jin, Eun-Sun Yang, Min Kyoung Cho, Dongryeol Ryu, Hao-Xian Yang, Sung-Jin Bae, Ki-Tae Ha   +12 more
doaj   +1 more source

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort

Lung Cancer
Osimertinib resistance inevitably occurs in EGFR mutated NSCLC. We aimed to identify resistance mechanisms (RM) using paired plasma and tumor samples in patients that progressed on 2nd/3rd line osimertinib.From 09 - 2019 to 02 - 2021, 51 patients were enrolled.
J.W.T. van der Wel, M. Jebbink, D. van den Broek, L.C. Steinbusch, W.S.M.E. Theelen, G. Ruiter, W. Buikhuisen, J.A. Burgers, P. Baas, M. Vermeulen, V. van der Noort, S.M.S. Hashemi, L.J.W. Bosch, K. Monkhorst, E.F. Smit, M.C. Boelens, A.J. de Langen   +16 more
openaire   +4 more sources